Broadcast Date: 
  • Time: 

Widespread adoption and availability of mRNA therapeutics hinges on overcoming significant manufacturing challenges related to scalability, cost-effectiveness, quality control, and regulatory compliance. Automated RNA production platforms can solve some of these challenges by implementing standardized processes from the research stage all the way through to the clinical and commercial stages. Standards minimize batch-to-batch variability, streamline technology transfers, enhance regulatory compliance, and ensure product stability throughout the development life cycle. They can also help unlock efficiency gains, reduce cycle times, and enhance cost-effectiveness.

In this GEN webinar, Patrick Thiaville, PhD, will explore the possibilities and potential impact of automated RNA production standards on the development of targeted treatments such as mRNA therapeutics and vaccines and personalized therapies. He’ll present data from a case study that demonstrates how automation can help biotech companies fast-track the progress of their therapies and facilitate broad access to RNA-based treatments. Learning objectives for this webinar include:

  • Identify the critical manufacturing bottlenecks impeding the widespread availability of transformative mRNA therapeutics and vaccines.
  • Discover how implementing standardized and automated RNA production processes from the earliest research stages can address scalability, quality, regulatory, and cost-efficiency challenges.
  • Evaluate the quantitative impact of automation strategies through an insightful case study, highlighting accelerated timelines, seamless tech transfers, and facilitated access to RNA-based therapies.
Patrick Thiaville
Patrick Thiaville, PhD
Chief Technology Officer, Nucleic Acids